Wells Fargo & Company Issues Positive Forecast for GE HealthCare Technologies (NASDAQ:GEHC) Stock Price

GE HealthCare Technologies (NASDAQ:GEHC) had its target price raised by equities research analysts at Wells Fargo & Company from $75.00 to $85.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would suggest a potential upside of 23.12% from the stock’s previous close.

A number of other research firms also recently weighed in on GEHC. Weiss Ratings downgraded shares of GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Evercore set a $80.00 price objective on shares of GE HealthCare Technologies in a research note on Thursday, April 30th. Hovde Group began coverage on GE HealthCare Technologies in a report on Friday, July 17th. They issued a “market perform” rating and a $14.00 price objective for the company. Piper Sandler reiterated a “buy” rating on shares of GE HealthCare Technologies in a report on Wednesday. Finally, Rothschild & Co Redburn reduced their price target on GE HealthCare Technologies from $110.00 to $98.00 in a research report on Thursday, April 30th. Ten equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GE HealthCare Technologies currently has a consensus rating of “Hold” and an average price target of $77.05.

GE HealthCare Technologies Trading Down 4.0%

NASDAQ:GEHC opened at $69.04 on Thursday. GE HealthCare Technologies has a twelve month low of $58.75 and a twelve month high of $89.77. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95. The business has a 50 day moving average price of $63.83 and a two-hundred day moving average price of $70.69. The company has a market cap of $31.41 billion, a P/E ratio of 16.63, a price-to-earnings-growth ratio of 1.74 and a beta of 0.72.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.26 billion. During the same period last year, the company earned $1.06 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. As a group, analysts expect that GE HealthCare Technologies will post 4.89 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James Saccaro acquired 3,310 shares of GE HealthCare Technologies stock in a transaction on Friday, May 1st. The stock was purchased at an average cost of $60.60 per share, with a total value of $200,586.00. Following the completion of the transaction, the chief financial officer directly owned 87,471 shares in the company, valued at $5,300,742.60. This trade represents a 3.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Watkin Phoebe L. Yang acquired 1,000 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was bought at an average price of $63.01 per share, for a total transaction of $63,010.00. Following the completion of the acquisition, the director owned 13,702 shares of the company’s stock, valued at approximately $863,363.02. The trade was a 7.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 15,928 shares of company stock worth $1,005,761. Company insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GEHC. Laurel Wealth Advisors LLC acquired a new stake in GE HealthCare Technologies during the fourth quarter worth approximately $26,000. Optima Capital LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $27,000. Godfrey Financial Associates Inc. bought a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $27,000. Montag A & Associates Inc. increased its stake in shares of GE HealthCare Technologies by 105.4% during the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock worth $28,000 after purchasing an additional 175 shares during the period. Finally, Transamerica Financial Advisors LLC lifted its holdings in GE HealthCare Technologies by 331.6% during the 4th quarter. Transamerica Financial Advisors LLC now owns 341 shares of the company’s stock worth $28,000 after purchasing an additional 262 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Key GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates. GE HealthCare reported adjusted EPS of $1.13, above the $1.04 consensus estimate, while revenue reached approximately $5.29 billion versus expectations of $5.26 billion. Revenue increased about 5.8% year over year. GE HealthCare reports second quarter 2026 financial results
• Positive Sentiment: Orders and backlog reached records. Orders grew 11.1% and the backlog climbed to $23.9 billion, improving visibility into future revenue. Management cited broad-based order growth and healthy hospital demand, particularly for diagnostic and imaging products. GEHC Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Growth was strongest in key businesses. Pharmaceutical Diagnostics benefited from demand for contrast media and radiopharmaceuticals, while Advanced Imaging Solutions gained from cardiovascular ultrasound and CT systems. These trends point to an improving healthcare-equipment replacement cycle. GE HealthCare beats quarterly profit estimates
• Positive Sentiment: BTIG raised its price target. BTIG Research increased its target from $75 to $79 and maintained a “buy” rating, signaling greater confidence in GEHC’s earnings momentum. Benzinga analyst coverage
• Neutral Sentiment: Options activity was unusually high. Investors purchased 8,956 GEHC call options, 45% above average daily call volume. This may indicate increased bullish speculation, although options activity alone does not confirm a sustained move. GE HealthCare Technologies sees unusually high options volume
• Negative Sentiment: Some earnings benefits were temporary. A tariff refund and lower tax rate contributed to the EPS beat, while adjusted EBIT margin narrowed by roughly 40 basis points. Patient Care Solutions also posted a significant organic revenue decline and negative EBIT; management is reviewing strategic alternatives for the unit.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.